UNSPSC 51142032: Prednazate

This classification denotes an analgesic and antipyretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71099P640P. European Medicines Agency schedules Prednazate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10013MIG. Prednazate generally arises in the molecular formula C25H32O8.C21H26CLN3OS.

The term PREDNAZATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) PREDNAZATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prednazate under HS 29372900 and SITC 54153. As of Q4 2014, PREDNAZATE remains the US FDA Preferred Term for this commodity. Prednazate bears US NLM identifiers UMLS ID C2826062 and NCI Concept Code C82228.

UNSPSC 51142032 Prednazate is a Commodity code that encompasses pharmaceutical products—specifically prescription medications and over-the-counter pharmaceutical preparations—procured by state and local health agencies, multistate cooperative purchasing alliances, and health and human services departments to support public health initiatives, community health programs, and state pharmacy benefit operations. State and local governments buy pharmaceuticals under this code through competitive bidding (IFB), requests for proposal (RFP), and requests for information (RFI) to source medications for direct distribution, pharmacy benefit programs, and emergency response initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance) that aggregate demand across multiple participating jurisdictions and states.

Recent opportunities span Florida, Texas, and Minnesota with multistate reach. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26, 2023 response deadline and quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling movement toward direct contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with a March 26, 2026 response deadline and July 1, 2026 contract effective date. MMCAP requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) and maintain $5 million commercial general liability insurance, with evaluation weighted 75 percent on price competitiveness and 25 percent split among fixed pricing, administrative compliance, EDI capability, and administrative fee terms.